

Erratum

A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity: Am J Cancer Res. 2021; 11(7): 3645-3659

Fanying Meng¹, Wan-Fen Li², Donald Jung¹, Chun-Chung Wang², Tianyang Qi¹, Chi-Sheng Shia², Ren-Yu Hsu², Yin-Cheng Hsieh², Jianxin Duan¹

¹Ascentawits Pharmaceuticals, LTD, Shenzhen, Guangdong, China; ²OBI Pharma, Inc., Taipei, Taiwan

Received October 12, 2023; Accepted October 24, 2023; Epub November 15, 2023; Published November 30, 2023

In this article, we would like to add the following funding information: This research was funded by the Development and Reform Commission of Shenzhen Municipality, Guangdong Province, P.R.C. (XMHT20220104029).

Therefore, we would like to publish this Erratum to reflect this change. We apologize for this error.

Address correspondence to: Jianxin Duan, Ascentawits Pharmaceuticals, LTD, Room 810, Building 5, Donghua Garden, Nanguang Road, Nanshan District, Shenzhen 518054, Guangdong, China. Tel: +86-13713681762; E-mail: jianxin.duan@ascentawitspharm.com